Mitsubishi Tanabe Pharma Canada Announces That Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in Alberta

TORONTO, June 1, 2020 /CNW/ -Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA (edaravone) is now listed on the Alberta Drug Benefit List formulary (special authorization).